Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
IMCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.15 - $39.33
Previous CloseN/A
Volume28.13K
Average Volume (3M)298.74K
Market Cap
$1.64B
Enterprise Value$1.13B
Total Cash (Recent Filing)$882.81M
Total Debt (Recent Filing)$44.40M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Nov 05, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding50,387,070
10 Day Avg. Volume306,807
30 Day Avg. Volume298,743
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue3.18
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda-108.13
Forecast
1Y Price Target
$59.11Price Target Upside81.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Financial PerformanceImmunocore reported strong Kimmtrak sales of $98M, handily beating consensus estimates.
Pipeline ExpansionThe robust revenue growth of KIMMTRAK supports the pipeline expansion, including autoimmune programs.
Revenue GrowthKimmtrak is approved in 39 countries and launched in 28, with increased demand and new country launches contributing to growth.
Bears Say
CompetitionBrenetafusp offers a scalable, off-the-shelf approach to targeting PRAME, one of the most broadly expressed cancer antigens across solid tumors.
Cost And ComplexityThe complexity, cost, and toxicity profile of autologous TCR T cell therapy underscore the competitive advantage of Immunocore's brenetafusp’s repeatable and combinable bispecific T cell engager mechanism.
Immunocore Holdings News
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $23.15 and its highest was $39.33 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is $1.64B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Aug 07, 2025. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.137 by -$0.063.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -0.24.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,387,070 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.137. Following the earnings report the stock price went down -0.53%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in IMCR
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.11 (81.26% Upside)
$59.11 (81.26% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.62%
12-Months-Change
Fundamentals
Return on Equity
-5.38%
Trailing 12-Months
Asset Growth
5.77%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
IMCR Company Deck
IMCR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased strong financial performance with significant growth in KIMMTRAK sales and global expansion. The company is advancing its pipeline with multiple Phase III trials and early-stage programs. While operating expenses have increased, the overall financial health remains robust, and growth is expected to moderate. The highlights significantly outweigh the lowlights, indicating a positive sentiment.View all IMCR earnings summariesIMCR Stock 12 Month Forecast
Average Price Target
$59.11
▲(81.26% Upside)
Technical Analysis
Travere Therapeutics
―
IDEAYA Biosciences
―
Disc Medicine
―
Vera Therapeutics
―
CG Oncology, Inc.
―
Ownership Overview
4.27% Insiders
32.82% Mutual Funds
0.06% Other Institutional Investors
62.04% Public Companies and
Individual Investors